Showing 7871-7880 of 9731 results for "".
- More than Half of US Cosmetics May Contain "Forever Chemicals"https://practicaldermatology.com/news/more-than-half-of-us-cosmetics-may-contain-pfas/2460842/More than half of the make-up products sold in the United States and Canada may contain toxic chemicals, a new study suggests. When researchers out of the University of Notre Dame tested 231 commonly used cosme
- Nutrafol Launches Postpartum Formulahttps://practicaldermatology.com/news/nutrafol-launches-postpartum-formula/2460838/The first-of-its-kind postpartum hair nutraceutical is now available from Nutrafol. Nutrafol Postpartum was developed with an OB/GYN to target the root causes of excess hair shedding and thinning post-pregnancy. It is intended to help the body recover from the physical stress of childbirth,
- Dermatologist Named as AMA President-Electhttps://practicaldermatology.com/news/dermatologist-named-as-ama-president-elect/2460835/Jack Resneck Jr, MD, a dermatologist from the San Francisco Bay Area, is the new president-elect of the American Medical Association (AMA). Following a year-long term as president-elect, Dr. Resneck will assume the office of AMA president in June 2022. “It is truly an honor t
- CellFX from Pulse Biosciences Cleared in Canadahttps://practicaldermatology.com/news/cellfx-from-pulse-biosciences-cleared-in-canada/2460833/The CellFX® System from Pulse Biosciences is now approved via a Medical Device License from Health Canada for use in dermatological procedures requiring ablation and resurfacing of the skin for the reduction, removal, and/or clearance of cellular-based benign lesions. Puls
- Dove, Conservation International Announce Million Dollar Forest Restoration Project to Fight Climate Changehttps://practicaldermatology.com/news/dove-conservation-international-announce-million-dollar-forest-restoration-project-to-fight-climate-change/2460822/Dove is launching the Dove Forest Restoration Project, one of the biggest protection and restoration efforts from any beauty brand to-date. The project is designed to protect and restore forests, protect the habitats of endangered species, and improve the livelihoods of 16,000 peo
- ASLMS Announces New Officershttps://practicaldermatology.com/news/aslms-announces-new-officers/2460816/Henry H.L. Chan, MD, PhD, FRCP, is the new President of the American Society for Laser Medicine and Surgery (ASLMS). Dr. Chan is currently the Honorary Clinical Professor and Honorary Consultant Dermatologist of the Division of Dermatology, Department of Medicine, The University of Hong
- Arcutis to Present New Data for Roflumilast in PsO at EADVhttps://practicaldermatology.com/news/arcutis-to-present-new-data-for-roflumilast-in-pso-at-eadv/2460798/New data from the DERMIS-1 and DERMIS-2 pivotal phase 3 studies evaluating roflumilast cream (ARQ-151) show that the investigational once daily, topical PDE4 inhibitor for psoriasis achieved the primary efficacy endpoint of IGA success at week eight for chronic plaque psoriasis. Data are being pr
- Dermavant: Posters Unveil Additional Data for Once-Daily Topical Tapinarofhttps://practicaldermatology.com/news/dermavant-posters-unveil-additional-data-for-once-daily-topical-tapinarof/2460770/Dermavant Sciences will present data in poster form from its two pivotal phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 and PSOARING 2, at AAD VMX 2021. Tapinarof is a novel, once-daily therapeutic aryl hydrocarbon recepto
- Zoom Dysmorphia Fuels Boost in Cosmetic Consultshttps://practicaldermatology.com/news/zoom-dysmorphia-fuels-boost-in-cosmetic-consults/2460760/During the pandemic, there was a shift to remote work, and demand for video conferencing increased which sired a corresponding rise in the number of patients with negative self-perceptions seeking cosmetic consultations, a new survey shows. In a survey of more than 100 board-certified d
- Favorable 5-Year Data for Janssen’s Tremfya in PsOhttps://practicaldermatology.com/news/favorable-5-year-data-for-janssens-tremfya-in-pso/2460758/Newly presented phase 3 data show that Tremfya® (guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through five years. Treatment impro